A Multicenter, Phase 1, Open-Label, Dose Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2018
At a glance
- Drugs ABBV 085 (Primary) ; Gemcitabine; Nivolumab; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 24 Aug 2018 Planned End Date changed from 28 Dec 2018 to 30 Jan 2019.
- 24 Aug 2018 Planned primary completion date changed from 29 Jun 2018 to 30 Nov 2018.
- 02 May 2018 Status changed from recruiting to active, no longer recruiting.